Differential expression of cyclooxygenase-2 in metastatic melanoma affects progression free survival. - Wikidata - wikimedia - TriplyDB

Differential expression of cyclooxygenase-2 in metastatic melanoma affects progression free survival.

Differential expression of cyclooxygenase-2 in metastatic melanoma affects progression free survival.

http://www.wikidata.org/entity/Q37636757

about

COX-2 expression positively correlates with PD-L1 expression in human melanoma cells.The Hydrogen Sulfide Releasing Molecule Acetyl Deacylasadisulfide Inhibits Metastatic Melanoma.Combination therapy of PKCζ and COX-2 inhibitors synergistically suppress melanoma metastasis.Hydrogen Sulfide Reduces Myeloid-Derived Suppressor Cell-Mediated Inflammatory Response in a Model of Helicobacter hepaticus-Induced Colitis.

P2860

Q37663388-3D79B2C6-3CDA-4065-96AD-7782ED6CD99A Q37667393-318583E9-C101-48EB-AF19-E42C665D1FB9 Q41595109-D3493E69-0187-40F8-8E58-64468B46E175 Q52595185-29524B14-CD8A-427F-9509-55D86A1F6F81

P2860

Differential expression of cyclooxygenase-2 in metastatic melanoma affects progression free survival.

http://www.wikidata.org/entity/Q37636757

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on August 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Differential expression of cyc ...... cts progression free survival.

@en

Differential expression of cyc ...... cts progression free survival.

@nl

type

label

Differential expression of cyc ...... cts progression free survival.

@en

Differential expression of cyc ...... cts progression free survival.

@nl

prefLabel

Differential expression of cyc ...... cts progression free survival.

@en

Differential expression of cyc ...... cts progression free survival.

@nl

P1433

Q37636757-8E3E5767-C6BF-4CEB-BC9B-F65687A2B678

P1476

Q37636757-869339EB-2603-4E30-957E-59DCBC3D2F4E

P2093

Q37636757-6A6CF861-A8E8-4538-8B47-9B58DD0B8AB5

Q37636757-70D33325-86FD-4CCF-956B-477983CFDDBC

Q37636757-81B5DC9F-350D-4764-91F2-63D4EFB79041

Q37636757-A19B12CE-27D7-4DB8-99A1-EF2896374845

Q37636757-ABBC8C91-6638-45ED-88A3-E5381C500957

Q37636757-F324706F-9A0D-4607-A4A6-6997EC72D735

Q37636757-FB8CD978-BD95-44FF-9CAC-82310E7F8BFD

P2860

Q37636757-12DD4357-487C-478C-8DAA-FD9B31357FAD

Q37636757-62146C42-C086-490E-8757-FA433AC8B12D

Q37636757-6678D912-1A47-4C74-8B3A-4F18791E62F7

Q37636757-75C4CBE8-D5DF-48D6-B6BB-BCB5BF8C114C

Q37636757-7F247E0B-7C53-409A-83BD-6ED752798673

Q37636757-874810AB-32E4-4125-B436-FDFB2C80C524

Q37636757-B17D67EC-904B-4548-B540-7B5B498D713E

Q37636757-CA319570-CEC0-4B2D-9702-752E7BC18D3F

Q37636757-F85564BD-D1B4-48A7-8DA8-EC493416133B

Q37636757-FDE2E932-BE4E-4AFF-BB84-3867FD23901F

P304

Q37636757-89096623-BFB5-48AA-B715-2ABADD0A4813

P31

Q37636757-F72D10F2-3BD3-4B9A-A361-34D6378B6E44

P356

Q37636757-815BB1AF-B550-4A65-AA39-5A9BB5917798

P407

Q37636757-CC93106A-858F-463B-A316-C3D54FF59C96

P433

Q37636757-FBC408B8-9B66-4D51-82E9-3A3E49808511

P478

Q37636757-74E29A13-B686-4BFA-9DD6-37F96E85D319

P50

Q37636757-186E605F-E207-4A83-BB98-F8B7038B4021

Q37636757-24FA7305-A994-4E42-B495-96FD6AF2C19A

P577

Q37636757-C599B7FF-CC95-4057-915A-426843971F7D

P698

Q37636757-7C5A2528-5547-4386-A729-6810AE11603A

P932

Q37636757-A2B865C5-4EE6-4E8E-97E0-D7EA52BDC953

P356

ONCOTARGET.10976

P1433

P1476

Differential expression of cyc ...... ects progression free survival

@en

P2093

Angela Ianaro

http://www.w3.org/2001/XMLSchema#string

Anna Maria Anniciello

http://www.w3.org/2001/XMLSchema#string

Chiara Armogida

http://www.w3.org/2001/XMLSchema#string

Elisabetta Panza

http://www.w3.org/2001/XMLSchema#string

Giuseppe Cirino

http://www.w3.org/2001/XMLSchema#string

Giuseppe Ercolano

http://www.w3.org/2001/XMLSchema#string

Paola De Cicco

http://www.w3.org/2001/XMLSchema#string

P2860

Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis

Expression of cyclooxygenase 2 in human malignant melanoma.

Eicosanoids and cancer

Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity.

Evidence that links loss of cyclooxygenase-2 with increased asymmetric dimethylarginine: novel explanation of cardiovascular side effects associated with anti-inflammatory drugs

Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs.

Role of the cystathionine γ lyase/hydrogen sulfide pathway in human melanoma progression.

Celecoxib exhibits the greatest potency amongst cyclooxygenase (COX) inhibitors for growth inhibition of COX-2-negative hematopoietic and epithelial cell lines.

COX-2 expression in malignant melanoma: a novel prognostic marker?

Cyclooxygenase-2 (COX-2): first immunohistochemical marker distinguishing early cutaneous melanomas from benign melanocytic skin tumours.

P304

57077-57085

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.10976

http://www.w3.org/2001/XMLSchema#string

P407

P433

35

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

Giosuè Scognamiglio

P577

2016-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27494851

http://www.w3.org/2001/XMLSchema#string

P932

5302974

http://www.w3.org/2001/XMLSchema#string